Volume 95 Issue 36 | pp. 8-9 | Concentrates
Issue Date: September 11, 2017

New synthetic heparin could improve blood-thinning treatments

Optimized sulfated polysaccharide could be safer or have more-reversible activity than existing synthetic and animal-derived versions
Department: Science & Technology
News Channels: Organic SCENE, Biological SCENE
Keywords: Drug development, heparin, blood clotting, synthesis

A new synthetic version of the sulfated polysaccharide heparin that could be safer or have more-reversible activity than currently approved versions of the anticoagulant has been produced in quantities that begin to approach those needed for commercialization. Three types of heparins are currently approved as blood thinners to treat clotting disorders and prevent clotting in people undergoing kidney dialysis and surgery. Unfractionated heparin and low-molecular-weight heparin, derived from pig intestines, are . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society